Departments of Nephrology, Hebei Key Laboratory of Vascular Calcifcation in Kidney Disease, Hebei Clinical Research Center for Chronic Kidney Disease, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, 050000, People's Republic of China.
Int Urol Nephrol. 2024 Jul;56(7):2421-2430. doi: 10.1007/s11255-024-03974-1. Epub 2024 Mar 7.
This study intended to scrutinize the effect of RFR time on adverse renal outcomes and mortality and try to define the cutoff of early RFR.
We conducted a literature search from database inception to February 2023. Outcome measures incorporated the progression of CKD, delivery of RRT, incidence of composite renal outcomes, and mortality. And pooled results were depicted as odds ratio (OR) and 95% confidence interval (CI).
A total of 11 studies were finally selected (507,989 patients, mean follow-up, 3.89 years). The results exhibited that the crude mortality was lower in patients with early RFR (OR = 0.39, 95% CI: 0.16-0.95, P = 0.037). In addition, patients with early RFR had a lower incidence of progression to CKD (OR = 0.38, 95% CI: 0.17-0.85, P < 0.018), RRT (OR = 0.37, 95% CI: 0.20-0.71, P = 0.03), and composite renal outcomes (OR = 0.18, 95% CI: 0.15-0.20, P < 0.001). CKD progression-related events were significantly higher in patients whose renal function recovered after 7 days (OR = 0.69, 95% CI: 0.47-1.09, P = 0.112) than in those whose renal function recovered within 7 days (OR = 0.23, 95% CI: 0.06-0.92, P = 0.038), and the risk of RRT was lower in patients who recovered within 7 days (OR = 0.32, 95% CI: 0.15-0.66, P = 0.002) than in those who recovered after 7 days (OR = 0.72, 95% CI: 0.17-3.09, P = 0.654) or longer.
Patients with early RFR had a lower risk of CKD progression, RRT, and composite renal outcomes, as well as lower crude mortality than those without early recovery, despite no marked difference in 30-day, 90-day, and 1-year mortality. We speculated that 7 days may be used as a cutoff for early RFR.
本研究旨在探讨 RFR 时间对不良肾脏结局和死亡率的影响,并尝试确定早期 RFR 的截止值。
我们从数据库创建开始到 2023 年 2 月进行了文献检索。研究结果包括 CKD 进展、RRT 的应用、复合肾脏结局的发生率和死亡率。汇总结果以比值比(OR)和 95%置信区间(CI)表示。
最终共纳入 11 项研究(共 507989 例患者,平均随访时间 3.89 年)。结果显示,早期 RFR 患者的粗死亡率较低(OR=0.39,95%CI:0.16-0.95,P=0.037)。此外,早期 RFR 患者发生 CKD 进展(OR=0.38,95%CI:0.17-0.85,P<0.018)、RRT(OR=0.37,95%CI:0.20-0.71,P=0.03)和复合肾脏结局(OR=0.18,95%CI:0.15-0.20,P<0.001)的发生率较低。肾功能在 7 天内恢复的患者(OR=0.69,95%CI:0.47-1.09,P=0.112)与肾功能在 7 天内恢复的患者(OR=0.23,95%CI:0.06-0.92,P=0.038)相比,CKD 进展相关事件发生率明显更高,而肾功能在 7 天内恢复的患者(OR=0.32,95%CI:0.15-0.66,P=0.002)的 RRT 风险低于肾功能在 7 天后恢复的患者(OR=0.72,95%CI:0.17-3.09,P=0.654)或更长时间。
与无早期恢复的患者相比,早期 RFR 患者的 CKD 进展、RRT 和复合肾脏结局风险较低,粗死亡率也较低,尽管 30 天、90 天和 1 年死亡率无显著差异。我们推测 7 天可能可以作为早期 RFR 的截止值。